33 results about "Colon adenocarcinoma" patented technology

The invention discloses application of a gene used as a biomarker in colon adenocarcinoma. It first discovered that proliferation, migration and invasion of colon adenocarcinoma cells can be changed by increasing expression of an ARFGEF3 gene in a patient suffering from the colon adenocarcinoma and reducing the expression level of ARFGEF3, and therefore, ARFGEF3 can be used for developing a product for early diagnosis of the colon adenocarcinoma and a drug for treating the colon adenocarcinoma. The application of the gene used as the biomarker in the colon adenocarcinoma provides a theory and experiment foundation for implementation of the precision medicine.

The invention provides a method for establishing orthotopic transplantation model of colorectal cancer, which comprises a) selecting and culturing colon adenocarcinoma cell line and preparing cell suspension; b) performing colostomy on living experimental animal; c) and inoculating the above colon adenocarcinoma cell suspension to submucosal stroma to allow natural growth. The biological traits such as route of metastasis of the transplanted adenocarcinoma cells are similar to that of the primary colon adenocarcinoma cell. The invention is advantageous in that the model is easy to be established, the transplanted colon adenocarcinoma locates at body surface so that it can be sampled and observed conveniently to meet the requirement for dynamic research, and the consumption of experimental animals can be reduced.

The invention discloses a molecular marker for colon adenocarcinoma. The molecular marker is LOC105377352, wherein the expression of the LOC105377352 in a patient of the colon adenocarcinoma is increased. The lncRNA (long non-coding Ribonucleic Acid) marker provided by the invention can be used for early diagnosis of the colon adenocarcinoma and has relatively high sensitivity and specificity.

The invention discloses a determination method for the absorption and transportation amount of six components in rhizoma bletillae in a Caco-2 cell model. The method comprises the steps of: preparing a rhizoma bletillae extract solution, a standard solution serving as a reference substance and an internal standard solution; establishing a human-derived colon adenocarcinoma cell line Caco-2 cell model; preparing a cell suspension through a Caco-2 cell model; determining the content of the six components by UPLC-MS/MS; determining the total protein content according to a Coomassie brilliant blue dye liquor protein determination kit method, and calculating the cell uptake X=the total protein of a to-be-determined substance. The invention adopts UPLC-MS/MS to establish the analysis method for the 6 components in a rhizoma bletillae extract, determines the influence of the rhizoma bletillae extract to absorption and uptake of Caco-2 cells under the conditions of time, concentration, temperature, pH and P-gh inhibitors, preliminarily evaluates the in vivo absorption characteristics of the rhizoma bletillae extract, and provides scientific basis for the research and development of the oral preparation of the rhizoma bletillae extract.

The present invention provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the present invention provides diagnostics and prognostics for colon (including colon adenocarcinoma) cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis.

The present invention provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the present invention provides diagnostics and prognostics for colon (including colon adenocarcinoma) cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis.

The invention relates to an application of a compound marsdenia tenacissima glycoside B which is extracted and separated from natural plant marsdenia tenacissima in the preparation of a drug for remedying tumour diseases including various malignant tumour diseases, such as ovary cancer, stomach cancer, liver cancer, leucocythemia, lung cancer, oral epidermoid carcinoma, rectal adenocarcinoma, breast cancer, malignant melanocarcinoma, colon adenocarcinoma, nasopharyngeal carcinoma, prostate cancer, etc. The invention also relates to a preparation technology of the marsdenia tenacissima glycoside B. After using water extraction and alcohol sedimentation, the invention uses an innovative chloroform extraction and aether sedimentation technology by chloroform extraction and also creatively adding aether, thereby reducing the content of impurity in extract obviously, and the marsdenia tenacissima glycoside B with high purity can be obtained just by silica gel column separation at a time. The method has high yield and simple operation, does not require a preparation type precision instrument of high performance liquid phase and other similar instruments and is closer to the requirement of the industrialized production.

The present invention provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the present invention provides diagnostics and prognostics for colon (including colon adenocarcinoma) cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis.

A MNase-Sequence Capture method, mTSS-seq, was developed herein to map genome-wide nucleosome distribution in cancer, for example primary human lung and colon adenocarcinoma tissue. Here, it was confirmed that nucleosome redistribution is an early, widespread event in lung adenocarcinoma (LAC) and colon adenocarcinoma (CRC). These altered nucleosome architectures are consistent between LAC and CRC patient samples indicating that they can serve as important early adenocarcinoma markers. As such, this consistency would be expected in other adenocarcinomas, as well as other carcinomas. It was demonstrated that the nucleosome alterations are driven by the underlying DNA sequence and potentiate transcription factor binding. DNA-directed nucleosome redistributions are widespread early in cancer progression, thus providing a methodology for early detection of cancer in grade one patients.

The invention discloses WFS1 (Wolfram 1) as a treatment target of rheumatoid arthritis and/or osteoarthritis. Hereby, the WFS1 can be used for developing products for diagnosing the rheumatoid arthritis and/or the osteoarthritis and developing drugs for treating the rheumatoid arthritis and/or the osteoarthritis. A research result of the invention provides fundamental basis for a clinicist to makean individual treatment program and is capable of providing a new drug target for development of colon adenocarcinoma drugs.

The invention discloses a manganese complex and the preparation method and application of the manganese complex, providing a complex of manganous, 1, 10-phenanthroline and sulfate. The preparation method is to stir the manganous, 1, 10-phenanthroline and sulfate in the solvent and the complex is acquired after reaction. The preparation method for the manganese complex has the advantages of easy access to the composite material, low cost, precipitation of crystal form with high purity and high yield, stable existence in natural state, good water soluble and fat-soluble performance, excellent inhibition effect to cells of lung cancer, liver cancer, colon adenocarcinoma and a plurality of cancers, wide action spectra and application range.

Formulations and methods for reducing blood glucose and/or increasing insulin signaling in a subject have been developed. The formulations include SBI-477 and compounds based on SBI-477 i.e., SBI-477 analogs (collectively, SBI-477 compounds) and/or Mondo family inhibitors, in an effective amount to inhibit intracellular lipid accumulation and/or increase cellular glucose uptake when compared to levels in a control subject not administered the composition. Also disclosed are methods of reducing intracellular lipid accumulation and/or increase glucose uptake in a subject in need thereof. The method includes administering to the subject an effective amount of SBI-477 compounds and/or Mondo family inhibitor to reducing intracellular lipid accumulation and/or increase glucose uptake in the subject. Also disclosed are method for treating one or more Myc-driven cancers, including neuroblastoma, lung squamous cell carcinoma/lung adenocarcinoma, liver hepatocellular carcinoma, colon adenocarcinoma, acute myeloid leukemia, and breast invasive carcinoma.

The present disclosure relates to the field of medicinal chemistry, and specifically to the use in the inhibition of tumor proliferation activity of ester derivatives of brefeldin A represented by Formula (I). The new compounds provided herein are prominent in the prevention or treatment of hyperproliferative diseases, including liver cancer, leukemia, breast cancer, colon adenocarcinoma, gastric cancer, lung cancer, Bart's esophageal cancer, cervical cancer, pancreatic cancer, endometrial cancer, bone cancer, lymphoma, kidney cancer, brain cancer, nerve cancer, nasopharyngeal cancer, oral cancer and colorectal cancer, and have the potential to be developed as novel antitumor agents.

The invention relates to a novel application of mir-3620, in particular to novel applications of the mir-3620 and mature miRNA thereof in diagnosing and treating colon adenocarcinoma. According to the novel application of the mir-3620, next generation sequencing is conducted on colon adenocarcinoma tissues and para-carcinoma tissues, so that data is obtained, and meanwhile, the obtained data is integrated and analyze in combination with existing data of a database, so that miRNA expression data is obtained and candidate mir-3620 is screened out. Further clinical verification and cell experiment results indicate that miR-3620-3p achieves low expression in the cancer tissues, and the over-expression of the miR-3620-3p can inhibit in vitro proliferation capacity of the colon adenocarcinoma cells. The invention provides a novel colon adenocarcinoma diagnosis and treatment gene for clinical application and lays a foundation for further research and development of related reagents.

The present disclosure relates to the field of medicinal chemistry, and specifically to brefeldin A derivatives represent by Formula (I) and its use in the inhibition of tumor proliferation activity. The new compounds provided herein are prominent in the prevention or treatment of hyperproliferative diseases, including liver cancer, leukemia, breast cancer, colon adenocarcinoma, lung cancer, Bart's esophageal cancer, gastric cancer, cervical cancer, pancreatic cancer, kidney cancer, endometrial cancer, nasopharyngeal cancer, bone cancer, lymphoma, brain cancer, nerve cancer, oral cancer and colorectal cancer, and have the potential to be developed as novel antitumor agents.